Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema. (PubMed, Ophthalmol Sci) - P3 | "The MEAD trial comprised two 3-year randomized, multicenter, sham-controlled, phase III clinical studies that evaluated the efficacy and safety of dexamethasone intravitreal implant (DEX-I) in patients with diabetic macular edema...These results suggest that patients treated with dexamethasone experience a longer time with clinically meaningful outcomes than with sham, such as being able to drive or regaining normal structural retinal features. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis. (PubMed, Am J Ophthalmol Case Rep) - "Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing. No scleral melt or ocular hypertension was noted 11 months after the first injection. Subconjunctival dexamethasone implant injection can be a well-tolerated treatment option for peripheral ulcerative keratitis."

Journal • Cardiovascular • Glaucoma • Keratitis • Ocular Inflammation • Ophthalmology

Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. (PubMed, BMC Ophthalmol) - P3 | "Treatment with DEX shortened the time to DME resolution compared with sham. Higher CRT was associated with longer time to DME resolution. These findings may influence therapeutic decisions."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. (PubMed, Int Ophthalmol) - "Early combined therapy with dexamethasone implant (Ozurdex) and Conbercept injections offers significant clinical benefits for the treatment of DME during the initial three months of treatment."

Clinical • Journal • Cataract • Diabetic Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Innovative surgical approach for persistent macular holes: the role of plasma rich in growth factors technology (SOE 2025) - "An intravitreal injection of a dexamethasone implant (Ozurdex®) was initially attempted without any benefit. This case demonstrates the effectiveness and safety of PRGF when used as an adjunctive treatment for persistent MH. While the use of PRGF in retina surgery shows promise, further research is needed to establish its efficacy, optimal concentration, timing, and mode of delivery."

Ophthalmology • Retinal Disorders

Eight-year follow-up of iluvien treated Diabetic Macular Edema (DME) patients: long term outcomes (SOE 2025) - "Iluvien may have an effect on DME beyond 3 years, as 33% (n=3) of our cohort stopped anti-VEGF and ozurdex injections 8 years after their 1st Iluviens. whilst 11% (n=1) of our cohort needed a 2nd Iluvein. 22% of patients (n=2) stayed completely intravitreal injection free at year 8."

Clinical • Diabetic Macular Edema • Glaucoma • Ophthalmology

Vogt-Koyanagi-Harada disease revealed by uveitis: a case report (SOE 2025) - "The probable form of VKH disease is relatively rare, but it should be considered when characteristic ocular signs are observed in the fundus. The early treatment is crucial for a favorable prognosis."

Case report • Clinical • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Presentation and outcomes of acute bacterial endophthalmitis secondary to Intravitreal Dexamethasone implant (SOE 2025) - "Endophthalmitis in the setting of Ozurdex results in variable visual outcomes. The most common causative organism is Staphylococcus epidermidis. Prompt treatment with broad-spectrum intravitreal antibiotics is highly recommended."

Diabetic Macular Edema • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology

Incidence and risk factors of ocular hypertension following ıntravitreal dexamethasone implantation: the role of baseline intraocular pressure. (PubMed, Int Ophthalmol) - "Intravitreal Ozurdex implantation is associated with a significant increase in IOP, necessitating close monitoring. Higher baseline IOP and male gender were identified as major risk factors. While the majority of cases were successfully managed with topical therapy, a small proportion required surgical intervention. Further research is warranted to improve risk stratification and optimize management strategies."

Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Dexamethasone intravitreal implant combines with VEGFR fusion protein versus VEGFR fusion protein alone for Diabetic Macular Edema: a multicentre, randomized, open-label clinical trial (ChiCTR) - P2 | N=98 | Completed | Sponsor: The Second Affiliated Hospital of Air Force Military Medical University,Chinese People’s Liberation Army; The Second Affiliated Hospital of Air Forc

New P2 trial • Diabetic Macular Edema • Ophthalmology

Delayed-Onset Endophthalmitis After Intravitreal Dexamethasone Implantation. (PubMed, J Vitreoretin Dis) - "Purpose: To present a series of cases of acute endophthalmitis after intravitreal (IVT) sustained-release dexamethasone implantation (Ozurdex) with an unusually delayed onset... Delayed-onset acute endophthalmitis after dexamethasone implantation represents a clinical challenge, potentially occurring up to weeks after the injection. Sustained suspicion for endophthalmitis is warranted given that cases may present beyond what is typical for postinjection endophthalmitis."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology

Predictive Value of Optical Coherence Tomography Biomarkers in Patients with Persistent Diabetic Macular Edema Undergoing Cataract Surgery Combined with a Dexamethasone Intravitreal Implant. (PubMed, Bioengineering (Basel)) - " The administration of DEX-I for DME refractory to anti-VEGF treatment in patients undergoing cataract surgery promoted functional improvements persisting longer than the anatomical ones. Patients presenting with DRIL, disrupted EZ, and higher CST at baseline may be better candidates for the combination of DEX-I and cataract surgery."

Biomarker • Journal • Cataract • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. (PubMed, Int J Ophthalmol) - "Intravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up."

Journal • Monotherapy • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

YAG Laser-Assisted Fragmentation of Dexamethasone Implants in the Anterior Chamber. (PubMed, Retina) - "Spontaneous migration of the dexamethasone intravitreal implant into the anterior chamber can occur in patients with aphakia, prior pars plana vitrectomy, or compromised capsular support. Timely intervention using Nd:yag laser can effectively fragment the dexamethasone implant, mitigating the risk of corneal endothelial damage and preserving visual function. In this cohort Nd:yag laser appeared a safe and effective treatment option for managing anterior chamber migration of the dexamethasone intravitreal implant, avoiding the need for more invasive surgical techniques or temporary non-invasive techniques."

Journal • Cataract • Macular Edema • Ophthalmology

Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis. (PubMed, J Ophthalmic Inflamm Infect) - "SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis."

Journal • Cardiovascular • Glaucoma • Immunology • Infectious Disease • Inflammatory Arthritis • Ocular Infections • Ocular Inflammation • Ophthalmology • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Scleritis • Vasculitis

Anterior chamber migration of an Ozurdex implant with Carlevale intraocular lens (PubMed, Ophthalmologie) - No abstract available

Journal

Subconjunctival dexamethasone implant (Ozurdex) in the management of refractory Non-Infectious anterior scleritis (J Ophthalmic Inflamm Infect) - "In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI."

Retrospective data • Eosinophilic Granulomatosis With Polyangiitis • Ophthalmology • Rheumatoid Arthritis

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (clinicaltrials.gov) - P1/2 | N=37 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Mar 2025

Trial completion • Trial completion date • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Blinded by Prostatic Adenocarcinoma - A Case of Cancer Associated Retinopathy with Multimodal Imaging. (PubMed, Ocul Immunol Inflamm) - "Inspite of intravenous methylprednisolone followed by oral steroids and therapeutic trial of antitubercular therapy, progression in the right eye threatening the fovea was noted in 9 days. Intravitreal ozurdex was given (OU) following which there was no progression. He also received mycophenolate mofetil 2 gm/day and hormonal therapy for the adenocarcinoma of the prostate...The autofluorescence and OCT show characteristic outer retinal involvement at the level of the RPE and photoreceptors. Intravitreal dexamethasone implant is a good option to prevent further vision loss."

Journal • Non Small Cell Lung Cancer • Ocular Melanoma • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Retinal Disorders

12-C-0107: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (clinicaltrials.gov) - P2 | N=55 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2028 ➔ Feb 2025

Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Smoldering Multiple Myeloma

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. (PubMed, J Clin Med) - " This retrospective study included patients from LMU University Hospital who were switched to Faricimab due to an inadequate response or adverse events related to prior intravitreal therapy (Ranibizumab, Aflibercept, or OzurdexTM). Given the small sample size and retrospective design, these findings should be interpreted as exploratory and hypothesis-generating. Further studies are needed to evaluate long-term efficacy and optimal treatment regimens."

Journal • Real-world evidence • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Effect of dexamethasone intravitreal implant on macular edema in vitrectomy eyes (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: The second hospital of Dalian Medical University; The second hospital of Dalian Medical University

New trial • Diabetic Macular Edema • Macular Edema • Ophthalmology

Switch to faricimab in various retinal diseases: real-world data (ARVO 2025) - "Previous treatments included bevacizumab, ranibizumab, aflibercept 2mg, brolucizumab, triamcinolone, and Ozurdex. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Outcomes of Diabetic Macular Edema During Pregnancy and the Postpartum (ARVO 2025) - "Nine eyes with pre-pregnancy DME received treatments including bevacizumab (1), Ozurdex (6), and Ranibizumab (2). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Cataract • Diabetic Macular Edema • Ophthalmology

Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review. (PubMed, Diagnostics (Basel)) - "Studies evaluating topical NSAIDs, periocular steroids, intravitreal triamcinolone acetonide (TCA), dexamethasone implants (Ozurdex), and intravitreal bevacizumab were included... Topical NSAIDs, particularly ketorolac and diclofenac, showed effectiveness in acute CMO, while their efficacy in chronic cases was variable... Topical NSAIDs, often combined with periocular steroids, serve as first-line therapy, with periocular steroids offering additional efficacy in resistant cases. Further research is needed to establish optimal treatment algorithms and improve outcomes for patients with post-operative CMO."

Journal • Review • Cataract • Macular Edema • Ophthalmology